Pfizer Thelin development (correction)
Executive Summary
Pfizer has commenced enrollment of patients in a Phase III study for Thelin (sitaxsentan) to support a U.S. filing for the treatment of pulmonary arterial hypertension. The "Sitaxentan Efficacy and Safety Trial With a Randomized Prospective Assessment of Adding Sildenafil" (SR-PAAS) is expected to be completed by June 2010. An article in "The Pink Sheet" inaccurately stated that Pfizer was likely to abandon a Thelin NDA (1"The Pink Sheet" Jan. 5, 2009, p. 8)
You may also be interested in...
FDA Not More Conservative Than EU, Jenkins Says; Investors Not Convinced
Perceptions that FDA is more conservative in its approval standards than its European regulatory counterpart are misguided and largely overblown, Office of New Drugs Director John Jenkins said
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.